Bayer's new cancer drug Stivarga has already added a notch to its belt. Cleared by the FDA last year to treat colorectal cancer, the drug is now approved as a treatment for a rare form of gastric cancer, gastrointestinal stromal tumors.
Embarrassed by the ads for erectile dysfunction drugs that pop up at the most inopportune moments? A new study found that the television commercials are indeed airing at family-viewing times--contrary to drugmakers' express promises to refrain.
In-licensed from Norway's Algeta, Alpharadin is one of the pharma company's top late-stage prospects, following a string of regulatory wins on the development front.
Europe's pharma community is revving up a drug discovery engine. A new effort involving 30 partners--including Bayer, Johnson & Johnson's Janssen and 5 other large pharmas--has launched to spark discovery of new treatments, using a crowdsourcing and open-innovation approach.
Bayer has raced to the FDA with its application for riociguat, a promising candidate for pulmonary hypertension and a key player in the pharma giant's plans for a blockbuster year in 2013 as it sets the stage for a high-profile market battle with two big competitors.
Seven major European drugmakers joined with other pharma companies, academics and other collaborators in a €196 million ($262.6 million) project to share and screen hundreds of thousands of compounds. Report
Europe's pharma community is revving up a drug-discovery engine. A new effort involving 30 partners--including Bayer, Johnson & Johnson's Janssen and 5 other large pharmas--has launched to spark discovery of new treatments, using a crowd-sourcing and open innovation approach.
What would top Xarelto for Bayer and Johnson & Johnson? Xarelto with an easy antidote.
France's drug regulators last year faced scathing criticism for dragging their feet when it came to the dangers of off-label use of diabetes drug Mediator. Now faced with consumer fears over deaths tied to off-label use of Bayer acne drug, Diane-35, they are acting with dispatch.
With a new chairman selected to take the helm of Novartis, lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week.